Panchsheel Organics FY26 Revenue ₹106.78 Cr, Net Profit ₹10.83 Cr; ₹0.80 Dividend Declared

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Panchsheel Organics FY26 Revenue ₹106.78 Cr, Net Profit ₹10.83 Cr; ₹0.80 Dividend Declared
Overview

Panchsheel Organics reported FY26 revenue of ₹106.78 crore and net profit of ₹10.83 crore. The company also recommended a final dividend of ₹0.80 per share.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Panchsheel Organics FY26 Results and Dividend

Panchsheel Organics reported annual revenue of ₹106.78 crore and a net profit of ₹10.83 crore for the financial year ended March 31, 2026.

For the fourth quarter ended March 31, 2026, the company posted revenue of ₹31.07 crore and a net profit of ₹1.70 crore.

Reader Takeaway: Stable annual financials and dividend payout confirmed; auditor gives clean chit.

What just happened

Panchsheel Organics Limited has announced its financial results for the fiscal year 2026. The company reported revenue from operations of ₹106.78 crore and a net profit of ₹10.83 crore for the full year.

Additionally, the results for the quarter ending March 31, 2026, showed revenue of ₹31.07 crore and a net profit of ₹1.70 crore.

Why this matters

These results provide shareholders with a clear picture of the company's annual performance. The recommended final dividend of ₹0.80 per share offers a direct return to investors, subject to shareholder approval.

An unmodified auditor opinion signals that the company's financial statements are presented fairly and without material misstatement, providing confidence to investors.

The backstory

Panchsheel Organics is involved in the manufacturing of pharmaceutical formulations. This filing represents a routine annual financial update.

What changes now

Shareholders will be able to assess the company's financial health for FY26. The dividend recommendation, if approved, will lead to a cash payout to eligible shareholders.

Risks to watch

While the results are stable and the auditor's opinion is unmodified, investors should monitor market conditions and the company's ability to maintain growth in the pharmaceutical sector.

Peer comparison

Information on specific peers and their financial performance is not available in this filing.

Context metrics

  • Revenue from operations (FY 2026): ₹106.78 crore
  • Net Profit (FY 2026): ₹10.83 crore
  • EPS (Basic) (FY 2026): ₹8.22
  • Final Dividend Recommended: ₹0.80 per share
  • Dividend Record Date: June 12, 2026

What to track next

Investors should look out for the Annual General Meeting where the dividend proposal will be voted upon. Monitoring future quarterly results and any new business developments will be key.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.